Abstract:Pairwise compatibility between virus and host proteins can dictate the outcome of infection. During transmission, both inter- and intraspecies variabilities in receptor protein sequences can impact cell susceptibility. Many viruses possess mutable viral entry proteins and the patterns of host compatibility can shift as the viral protein sequence changes. This combinatorial sequence space between virus and host is poorly understood, as traditional experimental approaches lack the throughput to simultaneously test all possible combinations of protein sequences. Here, we created a pseudotyped virus infection assay where a multiplexed target-cell library of host receptor variants can be assayed simultaneously using a DNA barcode sequencing readout. We applied this assay to test a panel of 30 ACE2 orthologs or human sequence mutants for infectability by the original SARS-CoV-2 spike protein or the Alpha, Beta, Gamma, Delta, and Omicron BA1 variant spikes. We compared these results to an analysis of the structural shifts that occurred for each variant spike's interface with human ACE2. Mutated residues were directly involved in the largest shifts, although there were also widespread indirect effects altering interface structure. The N501Y substitution in spike conferred a large structural shift for interaction with ACE2, which was partially recreated by indirect distal substitutions in Delta, which does not harbor N501Y. The structural shifts from N501Y greatly influenced the set of animal orthologs the variant spike was capable of interacting with. Out of the thirteen non-human orthologs, ten exhibited unique patterns of variant-specific compatibility, demonstrating that spike sequence changes during human transmission can toggle ACE2 compatibility and potential susceptibility of other animal species, and cumulatively increase overall compatibilities as new variants emerge. These experiments provide a blueprint for similar large-scale assessments of protein compatibility during entry by diverse viruses. This dataset demonstrates the complex compatibility relationships that occur between variable interacting host and virus proteins. The proteins encoded by a viral pathogen must be compatible with the proteins encoded by the host organism to allow the virus to enter and take over their cells. As the SARS-CoV-2 pandemic progressed, various SARS-CoV-2 variants of concern emerged, each altering the sequence of their spike proteins. We developed a new high-throughput infection assay which allowed us to simultaneously test dozens of sequence variants of ACE2 for their ability to allow viral particles coated with the spike proteins from the SARS-CoV-2 variants of concern to enter the cell. We found that the SARS-CoV-2 variant spike proteins only slightly changed in the way they interacted with human ACE2 but exhibited more pronounced changes in their ability to interact with ACE2 versions from other species. The SARS-CoV-2 spike variants generated during the pandemic were collectively compatible with the majority of animal ACE2 sequence versions we tested. We speculate that similar molecular interplays may occur during cross-species transmission, where repeated transmission and escape from immune responses allows the virus to simultaneously explore new molecular compatibilities with different receptor protein versions, thus allowing spread to new species.

In silico mutagenesis of human ACE2 with S protein and translational efficiency explain SARS-CoV-2 infectivity in different species

Investigation of the Genetic Variation in ACE2 on the Structural Recognition by the Novel Coronavirus (Sars-Cov-2)

Susceptibility and transmissibility of SARS-CoV-2 variants in transgenic mice expressing the cat angiotensin-converting enzyme 2 (ACE-2) receptor

In silico comparison of spike protein-ACE2 binding affinities across species; significance for the possible origin of the SARS-CoV-2 virus

Evaluating angiotensin-converting enzyme 2-mediated SARS-CoV-2 entry across species

Molecular dynamic simulation analysis of SARS-CoV-2 spike mutations and evaluation of ACE2 from pets and wild animals for infection risk

Key Mutations on Spike Protein Altering ACE2 Receptor Utilization and Potentially Expanding Host Range of Emerging SARS-CoV-2 Variants

Pseudotyped virus infection of multiplexed ACE2 libraries reveals SARS-CoV-2 variant shifts in receptor usage

Insights on cross-species transmission of SARS-CoV-2 from structural modeling

Comparison of SARS-CoV-2 spike protein binding to human, pet, farm animals, and putative intermediate hosts ACE2 and ACE2 receptors

Effect of SARS-CoV-2 spike mutations on animal ACE2 usage and in vitro neutralization sensitivity

ACE2 and TMPRSS2 distribution in the respiratory tract of different animal species and its correlation with SARS-CoV-2 tissue tropism

Computational insights into differential interaction of mamalian ACE2 with the SARS-CoV-2 spike receptor binding domain

Molecular simulation studies of the interactions between the human/pangolin/cat/bat ACE2 and the receptor binding domain of the SARS-CoV-2 spike protein

Predicting the Animal Susceptibility and Therapeutic Drugs to SARS-CoV-2 Based on Spike Glycoprotein Combined With ACE2

Analysis of ACE2 Gene-Encoded Proteins Across Mammalian Species.

Bioinformatic Evaluation of the Potential Animal Models for Studying SARS-Cov-2

Analysis the Molecular Similarity of Least Common Amino Acid Sites in ACE2 Receptor to Predict the Potential Susceptible Species for SARS-CoV-2

Key Residues Influencing Binding Affinities of 2019-Ncov with ACE2 in Different Species

Broad and Differential Animal Angiotensin-Converting Enzyme 2 Receptor Usage by SARS-CoV-2